CytomX Therapeutics (CTMX) EBIAT (2016 - 2025)
CytomX Therapeutics (CTMX) has disclosed EBIAT for 12 consecutive years, with -$14.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 348.06% year-over-year to -$14.2 million, compared with a TTM value of $28.0 million through Sep 2025, up 102.59%, and an annual FY2024 reading of $31.9 million, up 5700.88% over the prior year.
- EBIAT was -$14.2 million for Q3 2025 at CytomX Therapeutics, down from -$154000.0 in the prior quarter.
- Across five years, EBIAT topped out at $23.5 million in Q1 2025 and bottomed at -$34.8 million in Q4 2021.
- Average EBIAT over 5 years is -$9.4 million, with a median of -$6.5 million recorded in 2024.
- Peak annual rise in EBIAT hit 2155.2% in 2024, while the deepest fall reached 501.1% in 2024.
- Year by year, EBIAT stood at -$34.8 million in 2021, then increased by 19.73% to -$28.0 million in 2022, then surged by 102.99% to $837000.0 in 2023, then soared by 2155.2% to $18.9 million in 2024, then crashed by 175.38% to -$14.2 million in 2025.
- Business Quant data shows EBIAT for CTMX at -$14.2 million in Q3 2025, -$154000.0 in Q2 2025, and $23.5 million in Q1 2025.